DOCSLIB.ORG

Programme European Human Genetics Conference 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Programme European Human Genetics Conference 2019 THE EUROPEAN SOCIETY OF HUMAN GENETICS EUROPEAN HUMAN GENETICS CONFERENCE 2019 Svenska Mässan | Gothenburg – Sweden | June 15 – 18 www.eshg.org @eshgsociety PROGRAMME facebook.com/eshg.org #eshg2019 GENERAL FLOORPLAN Site Map Level 2 Site Map Level 2 G4 H2 Preview G2+G3 Centre K1 Hall H G4 H2 Preview Aisle G 2+G3 G Lounge K2+K3 Centre K1 Hall H Level 25 Level 29 F1+F2+F3 K2+K3 Aisle G G Lounge Upper House Imagine Level 23 Dining J Lounge Level 25 Level 29 F1+F2+F3 Upper House Heaven 23 Imagine Level 23 Dining J Lounge Lounge K Heaven 23 Aisle F Level 28 Lounge Level 3 View Horizon F4+F5 K Aisle F Level 28 Skyline Star Level 3 R38 View Horizon F4+F5 R37 1 R36 Skyline Star R31 R35 R34 R38 R37 1 F Lounge R33 R2 R17 R18 R36 R31 R35 R34 F Lounge R33 R2 R9 R11 R12 R13 R17 R18 Conference Reception Bryggan R21 R26 R3 R9 R7 R11 R12 R14R13 R22 ConferenceR25 R6 Reception R16 Bryggan R23 R24 R4 R5 R15 R21 R26 R3 R7 R14 R22 R25 R6 R16 R23 R24 R4 R5 R15 Level 1 Level 1 Hall E Hall D A1 Hall E Networking Mixer A3 Hall D A1 Networking Mixer A3 Coffee A4 & Café Special Lunch (Warm & Cold) Coffee A2 Coffee & A4 & Café Cold Regular Lunch Special Lunch (Warm & Cold) Coffee A2 Hall C Exhibition Hall & A5 Cold Regular Lunch Poster Area A5 Hall C Exhibition Hall e-Posters & Restaurant Live Stream Registration Coffee Poster Area Area & e-Posters Warm Regular Lunch & Restaurant Exhibition Live Stream Registration Coffee Service Desk Area & Warm Regular Lunch Exhibition Entrance 2 Service Desk Lounge ATM twentyfourseven Entrance11.3 2 Hotel Reception West Coast Lounge EntranceATM No. 5 twentyfourseven 11.3 Hotel Reception West Coast Elevator to Heaven 23 Hotel Entrance Entrance No. 5 Main Entrance No. 2 Elevator to Heaven 23 Hotel Entrance (Level 0) Main Entrance No. 2 (Level 0) Entrance 2 ESHG 2019 | Gothenburg, Sweden | www.eshg.org Entrance THE EUROPEAN SOCIETY OF HUMAN GENETICS EUROPEAN HUMAN GENETICS CONFERENCE 2019 Svenska Mässan | Gothenburg – Sweden | June 15 – 18 PROGRAMME ESHG 2019 | Gothenburg, Sweden | www.eshg.org 3 GENERAL TABLE OF CONTENTS General Floorplan 2 Welcoming Address 5 GENERAL Committees - Board - Organisation 6 Acknowledgements 7 Future European Human Genetics Conferences 7 CME Credits 7 Get the most out of the ESHG 2019 8 Session Type Descriptions 9 Programme at a Glance - Saturday 10 Programme at a Glance - Sunday 11 SATURDAY Programme at a Glance - Monday 12 Programme at a Glance - Tuesday 13 Poster Topics 14 Poster Topics - Technical Information 14 ESHG Scientific Programme Saturday, June 15 15 SUNDAY Sunday, June 16 21 Monday, June 17 29 Tuesday, June 18 37 Programme Information Sponsored Session, Saturday, June 15 44 Corporate Satellites, Saturday, June 15 - Monday, June 17 45 Business and Ancillary Meetings 54 MONDAY ESHG Award & Mendel Lectures 55 ESHG Award Lecturer Interview 56 Mendel Lecturer Interview 57 Young Investigator Award Candidates 58 Poster Award Finalists 62 Information General Information 64 TUESDAY Registration Fees 68 Networking Events 69 Exhibition Plan 70 List of Exhibitors 71 Exhibition Information (see the Exhibition Catalogue for more information) 72 SATELLITES AWARDS INFORMATION 4 ESHG 2019 | Gothenburg, Sweden | www.eshg.org GENERAL WELCOMING ADDRESS GENERAL Dear Colleagues and Friends, On behalf of the board of the European Society of Human Genetics, it is my privilege to invite you to the annual European Human Genetics Conference, which in 2019 will take place in the beautiful city of Gothenburg, Sweden, from the 15th to the 18th of June As a Norwegian I am especially pleased to welcome you to a meeting in Scandinavia that will let you experience the famous Scandinavian mid-summer If you have time I recommend to SATURDAY stay a few extra days to experience the magnificent Swedish west coast The purpose of our annual meetings is threefold: to give you excellent science, to teach you human genetics, and to provide an optimal environment for making new contacts and finding new friends Our Scientific Programme Committee (SPC) has worked hard to invite the best speakers from various sectors of human genetics, and to select the best abstracts for platform presentations The scientific content is thus a nice and balanced mixture of invited talks (the concurrent symposia) and selected abstract presentations (the concurrent sessions) Throughout the meeting we also provide educational talks for those of you that are not that scientific, or that need to get updated or get an overview on various topics (that Gunnar Houge, President SUNDAY probably means all of you) These educational talks are also given by invited speakers, all European Society of Human Genetics with expert general knowledge of their subject A unique and usually fondly memorable event of our conferences is the Monday evening party This is not only arranged for the young but also for those that want to feel young – and those that just want to meet and talk to friends in a relaxed atmosphere As a bonus you get good food and excellent music – for an affordable and subsidized price As you hopefully have noticed, ESHG is everything you need in human genetics, whatever MONDAY your professional background is Our exhibitors also enjoy this plurality, showcasting their range of products for both clinical and laboratory work We hope to see as many of you as possible in Gothenburg, and hope you will return back home with the feeling that the ESHG meeting is a major meeting in human genetics that you really do not want to miss Gunnar Houge President European Society of Human Genetics TUESDAY Swedish Society of Medical Genetics and Genomics Dear Colleagues and Friends, On behalf of the board of the Swedish Society of Medical Genetics and Genomics, it is my SATELLITES privilege to welcome you to the annual European Human Genetics Conference 2019 in the city of Gothenburg, Sweden I am pleased to invite you to this event in Scandinavia and grateful for the work by ESHG and the programme committee that has resulted in a very interesting program with a balanced mix of educational talks and the latest in human genetics, both basic and applied Thus, we are looking forward to a highly inspirational meeting Gothenburg is the largest non-capital in the Nordics and located on the beautiful west coast of Sweden and I hope that you also have a chance to explore it in conjunction with the AWARDS meeting and, if the weather permit, to enjoy the bright summer evenings However, one must go much further north in Sweden to experience midnight sun Finally, the meeting is an opportunity to meet old friends, new colleagues and making new collaborations Magnus Burstedt President of the Swedish Society of Medical Genetics and Genomics INFORMATION WELCOME ESHG 2019 | Gothenburg, Sweden | www.eshg.org 5 GENERAL COMMITTEES - BOARD - ORGANISATION European Society of Human Genetics Executive Board 2018-2019 Scientific Programme Committee President Chair Gunnar Houge, NO Joris Veltman, UK President-Elect Members GENERAL Alexandre Reymond, CH Yasemin Alanay, TR Ramona Moldovan, RO Vice-President Valerie Cormier-Daire, FR Carla Oliveira, PT Christine Patch, UK Jose Luis Costa, PT Matti Pirinen, FI Elfride de Baere, BE Lucy Raymond, UK Secretary-General Vita Dolzan, SI Alexandre Reymond, CH Karin Writzl, SI Edward Dove, UK Sam Riedijk, NL Deputy Secretary-General Francesca Forzano, UK Sini Skarp, FI Carla Oliveira, PT Brunella Franco, IT Maria Jesus Sobrido, ES SATURDAY Treasurer Lude Franke, NL Maria Soller, SE Andrew Read, UK Jens Michael Hertz, DK Malte Spielmann, US Executive Officer Martin Kircher, DE Asbjörg Stray-Pedersen, NO Jerome del Picchia, AT Maris Laan, EE Zeynep Tümer, DK Conxi Lazaro, ES Enza Maria Valente, IT Celine Lewis, UK Thierry Voet, UK Cecilia Lindgren, UK Karin Writzl, SI Annual Meetings Committee 2019 SUNDAY Chair Members Advisors Andrew Read, UK Gunnar Houge, President Jerome del Picchia, Executive Officer of the ESHG Alexandre Reymond, President-elect Jantie de Roos, Rose International Christine Patch, Vice-President Flora van Laer, Rose International Karin Writzl, Secretary-general Oscar Pacheco, Wiener Medizinische Akademie GmbH Carla Oliveira, Deputy Secretary-general Sarah Pirklbauer, Wiener Medizinische Akademie GmbH Andrew Read, Treasurer Joris Veltman, Chair of the SPC MONDAY Board Members Liaison Members Kristiina Aittomäki, FI Aleš Maver, SI Han Brunner, NL Marta Bertoli, UK Philippos Patsalis, CY Francesca Forzano, UK Olaf Bodamer, US Rebecka Ann Pestoff, SE Helena Kääriäinen, FI Isabella Ceccherini, IT Djana Plaseska-Karanfilska, MK Thomas Liehr, DE Angus John Clarke, UK Inga Prokopenko, UK Milan Macek, CZ Jill Clayton-Smith, UK Feliciano Ramos, ES Hans Scheffer, NL Johan den Dunnen, NL André Reis, DE Gert Jan van Ommen, NL TUESDAY Francesca Forzano, UK Olaf Riess, DE Joris Veltman, UK Josef Gecz, AU Sergio Sousa, PT Christian Gilissen, NL Zeynep Tümer, DK Kinga Hadzsiev, HU Birute Tumiene, LT Ellen Heitzer, AT Hilde Van Esch, BE Robert Hofstra, NL Reiner A Veitia, FR Bart L Loeys, BE ESHG Office European Society of Human Genetics c/o Vienna Medical Academy T: +43 1 405 13 83 35 / 41 SATELLITES Andrea Robinson Alser Strasse 4, 1090 Vienna, AT F: +43 1 407 82 74 Alissa McGregor www eshg org E: office@eshg org, membership@eshg org European Human Genetics Conference 2019 Conference Organiser Exhibition, Sponsoring and Hotel Accommodation ESHG 2019 Congress Office Corporate Satellites MCI Amsterdam AWARDS Wiener Medizinische Akademie GmbH ROSE INTERNATIONAL Schipluidenlaan 4, 1062 HE Oscar Pacheco, Sarah Pirklbauer Exhibition Management and
Load more

Recommended publications
  • 5 EVENTS in ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland
    FIFTH ANNUAL - LIFE SCIENCE R&D DATA INTELLIGENCE LEADERS FORUM Basel, Switzerland January 23-24th, 2018 Optional Workshop 22nd, January Hear keynote presentations from the experts: Etzard Stolte Global Head Knowledge Management Roche, Switzerland Abhimanyu Verma 5 EVENTS IN ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland Day 1: Torsten Niederdraenk Head of Technology Center Strategic Developments in R&D Big Siemens Healthcare, Germany Data Catherine Brownstein Scientific Director Day 2 (am): Stream 1 Manton Center for Orphan Disease Research Boston Children’s Hospital, USA Discovery & Omics Data Excellence Navin Ramachandran Radiology Consultant Day 2 (am): Stream 2 University College London Hospitals NHS Foundation Trust, Healthcare specialist in distributed ledgers and IoT Clinical & Patient Level Data IOTA Foundation, UK Excellence Marie-Claire Peakman Executive Director, Head Hit Discovery & Lead Profiling, Medicine Design Day 2 (pm): Stream A Pfizer, USA R&D IT & Bioinformatics Alex Zhavoronkov Co-founder, Insilico Medicine, CSO Day 2 (pm): Stream B The Biogerontology Research Foundation, UK Ivana Schnur Digital Health Collaborations Co-founder, CMO Sense.ly, USA Pre-Event Workshop: Jan 22nd Paul Wicks Artificial Intelligence for Drug Vice President of Innovation PatientsLikeMe, UK Discovery: Workshop for Senior Jazz Panchoo Global Strategy Head, VP, Digital Platforms Executives Ascensia Diabetes Care, Switzerland This Event is Certified for Continuing Professional Development with more than 30 presentations
    [Show full text]
  • Structural Study of the Acid Sphingomyelinase Protein Family
    Structural Study of the Acid Sphingomyelinase Protein Family Alexei Gorelik Department of Biochemistry McGill University, Montreal August 2017 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy © Alexei Gorelik, 2017 Abstract The acid sphingomyelinase (ASMase) converts the lipid sphingomyelin (SM) to ceramide. This protein participates in lysosomal lipid metabolism and plays an additional role in signal transduction at the cell surface by cleaving the abundant SM to ceramide, thus modulating membrane properties. These functions are enabled by the enzyme’s lipid- and membrane- interacting saposin domain. ASMase is part of a small family along with the poorly characterized ASMase-like phosphodiesterases 3A and 3B (SMPDL3A,B). SMPDL3A does not hydrolyze SM but degrades extracellular nucleotides, and is potentially involved in purinergic signaling. SMPDL3B is a regulator of the innate immune response and podocyte function, and displays a partially defined lipid- and membrane-modifying activity. I carried out structural studies to gain insight into substrate recognition and molecular functions of the ASMase family of proteins. Crystal structures of SMPDL3A uncovered the helical fold of a novel C-terminal subdomain, a slightly distinct catalytic mechanism, and a nucleotide-binding mode without specific contacts to their nucleoside moiety. The ASMase investigation revealed a conformational flexibility of its saposin domain: this module can switch from a detached, closed conformation to an open form which establishes a hydrophobic interface to the catalytic domain. This open configuration represents the active form of the enzyme, likely allowing lipid access to the active site. The SMPDL3B structure showed a narrow, boot-shaped substrate binding site that accommodates the head group of SM.
    [Show full text]
  • Investigation of Adiposity Phenotypes in AA Associated with GALNT10 & Related Pathway Genes
    Investigation of Adiposity Phenotypes in AA Associated With GALNT10 & Related Pathway Genes By Mary E. Stromberg A Dissertation Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY GRADUATE SCHOOL OF ARTS AND SCIENCES in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY In Molecular Genetics and Genomics December 2018 Winston-Salem, North Carolina Approved by: Donald W. Bowden, Ph.D., Advisor Maggie C.Y. Ng, Ph.D., Advisor Timothy D. Howard, Ph.D., Chair Swapan Das, Ph.D. John P. Parks, Ph.D. Acknowledgements I would first like to thank my mentors, Dr. Bowden and Dr. Ng, for guiding my learning and growth during my years at Wake Forest University School of Medicine. Thank you Dr. Ng for spending so much time ensuring that I learn every detail of every protocol, and supporting me through personal difficulties over the years. Thank you Dr. Bowden for your guidance in making me a better scientist and person. I would like to thank my committee for their patience and the countless meetings we have had in discussing this project. I would like to say thank you to the members of our lab as well as the Parks lab for their support and friendship as well as their contributions to my project. Special thanks to Dean Godwin for his support and understanding. The umbrella program here at WFU has given me the chance to meet some of the best friends I could have wished for. I would like to also thank those who have taught me along the way and helped me to get to this point of my life, with special thanks to the late Dr.
    [Show full text]
  • Swiss Biotech Report – "Agility, Leadership and Innovation in the Time of COVID-19” – Is Indeed Appropriate
    SwissSwiss BiotechBiotech ReportReport 2021 2019Agility, leadership and innovation in the time of COVID-19 Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra Swiss Confederation Innosuisse – Swiss Innovation Agency “The biopharma industry’s response to COVID-19 has truly been a global one – with Swiss companies and academic institutions at the forefront. Swiss-based biopharma players are contributing across the spectrum of patient needs.” George Scangos | Vir Biotechnology, Inc. “2020 was the best year ever for Swiss biotech in relation to financing activities, with a total of approximately CHF 3.4B raised” Jürg Zürcher | GSA Biotechnology Leader, EY “Compared to 2019, trading volumes rose sharply by 177% and the total free float market capitalization of all SIX-listed biotech companies was up 30% on 2020.” Fabian Gerber | SIX Agility, leadership and innovation in the time of COVID-19 “Technologies developed by scientists in Switzerland have been crucial in the fight against COVID-19, including cloning the virus, cryo electron microscopy to visualize the spike proteins, and the use of radioactive molecules that bind to receptor proteins to investigate how the virus enters the host.” Florian Fisch | Swiss National Science Foundation “On May 1 2020, Moderna and Lonza announced a strategic collaboration to enable manufacturing of up to 1 billion doses of the vaccine per year. Lonza acquired equipment and built the production lines in just 8 months.” Jan Lucht | scienceindustries “Industrial
    [Show full text]
  • European Human Genetics Conference 2017 Programme
    There’s nothing more 1967 - 2017 | 50th Anniversary Meeting personal than genomics Discover genomic solutions across the research continuum Visit us at stand 140 and discover how our portfolio of next-generation sequencing (NGS), microarray and informatic solutions can help empower your next breakthrough. EUROPEAN HUMAN Come learn how you can become a part of the scientic innovation happening in: GENETICS CONFERENCE 2017 • Complex Diseases • Rare or Undiagnosed Genetic Diseases Bella Center | Copenhagen, Denmark | May 27 - 30 • Reproductive Health • Cancer Genetics • Microbiology Experience the NovaSeq™ Series Discover a leap forward in technology by attending one of our stand presentations, or take a virtual reality tour. Attend the Illumina Satellite Workshop Sunday, 28 May | 19.15 – 20.45 | Room Ballerup Anniversary Meeting | Programme | European Human Genetics Conference 2017 | Copenhagen - Denmark 2017 | Copenhagen Human Genetics Conference | European Anniversary Meeting | Programme th 1967 - 2017 | 50 www.illumina.com Programme For Research Use Only. Not for use in diagnostic procedures. © 2017 Illumina, Inc. All rights reserved. European Society www.eshg.org @eshgsociety of Human Genetics facebook.com/eshg.org #eshg2017 GENERAL FLOORPLAN METRO Ground Floor Ballerup LECTURE HALLS B - CORPORATE SATELLITES Berlin Barcelona Brussels Birmingham Belgrade WC WC WC WC Bags Registration CENTERHALL Exhibition Service WC Athens Lead Retrieval Poster Printing LECTURE HALLS A Cambridge Gastro Café Exhibition Aarhus Centre Coffee & Lunch Preview Copenhagen Cash Bar MAIN LOBBY Live Stream Posters Amsterdam E-Posters WC AC Hotel FOYER Bella Sky LECTURE HALLS C Cannes Main Entrance Cologne First Floor 5 Athens CENTERHALL 16 17 WC 18 25 A Aarhus 18 19 20 LECTURE HALLS A Amsterdam MAIN LOBBY FOYER Ancona conf.
    [Show full text]
  • Chromosomal Microarray Analysis in Turkish Patients with Unexplained Developmental Delay and Intellectual Developmental Disorders
    177 Arch Neuropsychitry 2020;57:177−191 RESEARCH ARTICLE https://doi.org/10.29399/npa.24890 Chromosomal Microarray Analysis in Turkish Patients with Unexplained Developmental Delay and Intellectual Developmental Disorders Hakan GÜRKAN1 , Emine İkbal ATLI1 , Engin ATLI1 , Leyla BOZATLI2 , Mengühan ARAZ ALTAY2 , Sinem YALÇINTEPE1 , Yasemin ÖZEN1 , Damla EKER1 , Çisem AKURUT1 , Selma DEMİR1 , Işık GÖRKER2 1Faculty of Medicine, Department of Medical Genetics, Edirne, Trakya University, Edirne, Turkey 2Faculty of Medicine, Department of Child and Adolescent Psychiatry, Trakya University, Edirne, Turkey ABSTRACT Introduction: Aneuploids, copy number variations (CNVs), and single in 39 (39/123=31.7%) patients. Twelve CNV variant of unknown nucleotide variants in specific genes are the main genetic causes of significance (VUS) (9.75%) patients and 7 CNV benign (5.69%) patients developmental delay (DD) and intellectual disability disorder (IDD). were reported. In 6 patients, one or more pathogenic CNVs were These genetic changes can be detected using chromosome analysis, determined. Therefore, the diagnostic efficiency of CMA was found to chromosomal microarray (CMA), and next-generation DNA sequencing be 31.7% (39/123). techniques. Therefore; In this study, we aimed to investigate the Conclusion: Today, genetic analysis is still not part of the routine in the importance of CMA in determining the genomic etiology of unexplained evaluation of IDD patients who present to psychiatry clinics. A genetic DD and IDD in 123 patients. diagnosis from CMA can eliminate genetic question marks and thus Method: For 123 patients, chromosome analysis, DNA fragment analysis alter the clinical management of patients. Approximately one-third and microarray were performed. Conventional G-band karyotype of the positive CMA findings are clinically intervenable.
    [Show full text]
  • Molecular Pathogenesis of a Malformation Syndrome Associated with a Pericentric Chromosome 2 Inversion
    UNIVERSIDADE DE LISBOA FACULDADE DE CIÊNCIAS DEPARTAMENTO DE BIOLOGIA ANIMAL Molecular pathogenesis of a malformation syndrome associated with a pericentric chromosome 2 inversion Manuela Pinto Cardoso Mestrado em Biologia Humana e do Ambiente Dissertação orientada por: Doutor Dezsö David Doutora Deodália Dias 2017 ACKNOWLEDGEMENTS I would like to say “thank you!” to all the people that contributed in some way to this thesis. First and foremost, I would like to express my deepest gratitude to my supervisor, Dr. Dezsö David, for giving me the opportunity to work in his research group and for everything he taught me. Without his mentorship I would have never learned so much. I am grateful for Prof. Deodália Dias’s encouragement and support in all these years that I have been under her wings. I would like to extent my thanks to everyone at the National Health Institute Dr. Ricardo Jorge, for their continuous help in all stages of this thesis. To the team at Harvard Medical School, thank you for the technical assistance, and in special Dr. Cynthia Morton and Dr. Michael Talkowski. I am also grateful to Dr. Rui Gonçalves and Dr. João Freixo, who accompanied this case study and shared their medical knowledge. Of course, I am grateful for the family members for their involvement in this study. To my lab mates, a shout-out to them all! I really hold them dear for their help and the many laughs we shared every day. Thank you Mariana for being there literally since day one and for playing the role of a more mature counterpart.
    [Show full text]
  • BOOKLET Santiago
    !1 14th International Symposium on Variants in the Genome: detection, sequencing & interpretation 5 - 7 June 2017 NH Collection Santiago Santiago de Compostela, Spain Scientific Programme Committee Prof. Johan T. den Dunnen (Leiden, Nederland) CHAIR Prof. Sir John Burn (Newcastle, UK) Prof. Angel Carracedo (Santiago de Compostela, Spain) Dr Reece Hart (San Francisco, CA, USA) Dr Andreas Laner (Munich, Germany) Dr Maria-Jesus Sobrido (Santiago de Compostela, Spain) Organising Committee Maria Torres (CEGEN-PRB2, Universidade de Santiago de Compostela) Rania Horaitis; Event Manager (Meeting Makers www.meeting-makers.com) Previous Meetings 2003 Palm Cove, Australia 1991 Oxford, UK 2005 Santorini, Greece 1993 Lago D’Orta, Italy 2007 Xiamen, China 1995 Visby, Sweden 2009 Paphos, Cyprus 1997 Brno, Czech Republic 2011 Santorini, Greece 1999 Vicoforte, Italy 2013 Lake Louise, Canada 2001 Bled, Slovenia 2015 Leiden, Netherlands !2 !3 !4 !5 !6 !7 !8 !9 !10 !11 !12 !13 Oral Presentation Abstracts Exomiser to include an assessment of SESSION 1 regulatory regions, in an application called the Genomiser. Simulations show an ability to rank the seeded causative variant in first place Phenotype Driven Genomic over an entire genome in over 60% of cases. Diagnostics In this talk, I will review how computational phenotype analysis with the HPO works and Peter N Robinson how we have used it for the Exomiser and Genomiser. Professor of Computational Biology, The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT 06032, USA CNV detection from targeted [email protected] next-generation panel sequencing www.jax.org Robinson lab: https://robinsongroup.github.io/ data in routine diagnostics Anna Benet-Pagès, Anke M.
    [Show full text]
  • Sophia GENETICS SA (Exact Name of Registrant As Specified in Its Charter)
    As filed with the Securities and Exchange Commission on July 23, 2021 Registration No. 333-__________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Rue du Centre 172, CH-1025 Saint-Sulpice, Switzerland (Address of Principal Executive Offices) SOPHiA GENETICS Incentive Stock Option Plan SOPHiA GENETICS 2019 Incentive Stock Option Plan (Full title of the plans) SOPHiA GENETICS, Inc. 185 Dartmouth Street, Suite 502 Boston, MA 02116 (Name and Address of Agent For Service) (617) 982-1210 (Telephone number, Including Area Code, of Agent For Service) Copies of all communications, including all communications sent to the agent for service, should be sent to: Kyoko Takahashi Lin Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 (212) 450-4000 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller reporting company o (Do not check if a smaller reporting company) Emerging Growth Company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
    [Show full text]
  • ESMO 2019 Exhibitors' List
    ESMO 2019 - Exhibitors' list (as of 21 of August 2019) Booth Number Company name 441 3D TECH OMEGA ZETA 469 3DforScience - Visuals for Bio & Health 235 10x Genomics 315 AbbVie 227 Abcam 213 Accord Healthcare 471 Adaptive Biotechnologies 208 Advanced Accelerator Applications, a Novartis company 465 Agendia 456 Alkermes, Inc 473 Almac Group 403 Amgen Inc. 415 Amoy Diagnostics Co., Ltd. 211 Aptitude Health 248 ArcherDX 309 Astellas 305 AstraZeneca 467 Avaden BioSciences, Inc. 463 Axiom Healthcare Strategies 446 Baxter 306 Bayer 419 BEACON Medicare Limited 443 BEIGENE, LTD. 233 Biocartis 245 Biotype GmbH 302 Bristol-Myers Squibb 401 Boehringer Ingelheim 238 Calithera Biosciences 476 Cancer Drug Interactions 407 Caris Life Sciences 225 CATALYSIS S.L. 318 CeGaT 215 Celgene 409 Celltrion Healthcare Co., Ltd. 454 Chemo Mouthpiece 450 Clinical Research Malaysia 217 Clovis Oncology 421 COMECER 411 Covance, Inc. 462 Cytel 205 Daiichi Sankyo, Inc. 413 DAVA Oncology 452 ECS Progastrin 207 Eisai Ltd. 229 Elevar 239 EntroGen 247 Erytech Pharma SA 440 Europital 402 EUSA Pharma 214 Exelixis, Inc. 303 F. Hoffmann-La Roche AG 458 Ferring Pharmaceuticals 244 FibroGen, Inc. 455 FRENCH HEALTHCARE 422 Fresenius Kabi 448 geneXplain GmbH 221 Genmab 404 GENOMIC HEALTH 206 GSK 249 Guardant Health 246 HalioDx 474 Halozyme Therapeutics 417 Helsinn Healthcare 445 HTG Molecular Diagnostics 251 IBM Watson Health 319 Illumina 477 ImaginAb, Inc. 216 Incyte Biosciences International Sàrl 242 Institut Curie 310 IPSEN 472 IQVIA Biotech 210 ITM Isotopen Technologien Muenchen AG 220 Janssen-Cilag International NV P432 Jiahui International Hospital 406 Kaiku Health 420 Kite, a Gilead Company 236 KoNECT (Korea National Enterprise for Clinical Trials) 475 Leica Biosystems 307 Lilly 237 Linical 204 Loxo Oncology, Inc.
    [Show full text]
  • Cynosure Aces Single-Audit Program Twice
    POLICY & REGULATION COMMERCIAL R&D An update on NEST real-world Mark Hitchman of Canon Medical Two firms nab US breakthrough evidence efforts, p. 6 Systems discusses market growth status, p. 22 strategies, p. 15 Medtech Issue 80 Pharma Intelligence Informa February 5, 2018 medtech.pharmaintelligence.informa.comInsight 'WE SURVIVED MDSAP': The final visit from the US agency that year was the last straw, she said. "That FDA inspection really made me Cynosure Aces Single-Audit Program want to get Cynosure involved in MDSAP because I cancelled a vacation to Indonesia Twice; Tells How Your Firm Can, Too to stay behind for that inspection," Hoy said. "That's when I learned that travel insurance SHAWN M. SCHMITT [email protected] doesn't consider an FDA inspection to be an emergency that's reimbursable." MDSAP , created by the International Medical Device Regulators Forum (IMDRF), allows firms to undergo only one audit by an accredited third party to satisfy quality regulations for five countries: the US, Can- ada, Brazil, Japan and Australia. The program runs on a three-year cycle, albeit with differing scopes for each audit. Firms are certified to MDSAP in the first year; in the second and third years, they submit to surveillance audits, which are typically quicker than a certification audit. The cycle then repeats, with recertification to MDSAP Shutterstock: alphaspirit Shutterstock: occurring in the fourth year, and so on. MDSAP ran as a pilot program for three or longtime quality and regulatory "It was particularly difficult that year to full years from January 2014 through expert Connie Hoy, the decision to be in the quality department at Cynosure December 2016, but is now a bona-fide F ditch the prying eyes of multiple because all we did was get audited.
    [Show full text]
  • People Recent Moves of Note in and Around the Biotech and Pharma Industries
    careers & recruitment People Recent moves of note in and around the biotech and pharma industries. held various leadership roles at Novartis, Turning Point Therapeutics has announced the appointment including development franchise head of of Siegfried Reich (photo) as executive vice president respiratory, development franchise head of and CSO. Reich has over 25 years of pharma and biotech primary care, and global head of clinical experience developing more than 20 drug candidates. He was operations, analytics and regions. most recently senior vice president of research and cofounder of eFFECTOR Therapeutics, and before that was vice Michael Quigley has joined Gilead Sciences president and head of drug discovery at SGX, vice president as senior vice president, research biology. and head of viral and ophthalmic diseases at Pfizer, and He was most recently vice president and director and head of medicinal chemistry at Agouron. head of Bristol-Myers Squibb’s thematic “With a strong commitment to build on the four internally discovered drug research center for tumor microenvironment candidates in our pipeline, we wanted to attract a proven leader and visionary CSO modulation and site head of its Redwood to advance our research strategy,” said Athena Countouriotis, president and CEO of City, California location. Turning Point. “Siegfried is an ideal fit for our team, with deep discovery and novel- target-identification expertise, and a proven track record of developing drug candidates Verana Health has appointed Matthew Roe for difficult-to-drug targets through disciplined discovery and medicinal, structure- and chief medical officer. Roe is a cardiologist fragment-based chemistry.” and clinical researcher who has spent over two decades at the Duke University School of Medicine and the Duke Clinical Research Robert Abraham has been named CSO Therapeutics.
    [Show full text]